AQUILA Daratumumab
AQUILA: Primary Results From the Phase III Trial of Daratumumab vs Active Monitoring for High-Risk Smoldering Multiple Myeloma

Released: December 13, 2024

Expiration: December 12, 2025

Activity

Progress
1
Course Completed